Clinical Trials Browser

Phase 2 × Skin Neoplasms × trametinib × Clear all

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Phase 2 Withdrawn

Melanoma, Skin Neoplasms